Pinometostat companion diagnostic - Epizyme/Abbott

Drug Profile

Pinometostat companion diagnostic - Epizyme/Abbott

Latest Information Update: 24 Apr 2013

Price : $50

At a glance

  • Originator Epizyme
  • Developer Abbott Laboratories; Epizyme
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Leukaemia

Most Recent Events

  • 18 Apr 2013 Clinical trials in mixed lineage Leukaemia (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top